Tesaro Directors Slam 'Innuendo' In Del. Suit Over $5.1B Sale

Law360 (May 11, 2021, 8:59 PM EDT) -- A class of Tesaro stockholders seeking damages for an allegedly underpriced $5.1 billion sale of the cancer drugmaker in 2018 came to Chancery Court with a suit "heavy on innuendo and speculation" but short of facts, an attorney for the company's board told a Delaware vice chancellor Tuesday.

Timothy R. Farrell of Ropes & Gray LLP, counsel for Tesaro Inc.'s directors and officers, told Vice Chancellor Morgan T. Zurn during a teleconferenced dismissal argument that GlaxoSmithKline acquired the company for 182% of its unaffected stock price in a deal approved by 83% of stockholders.

"The vast majority of Tesaro's disinterested stockholders...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!